A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
Recruiting · NCT07517250 · Observational (researchers observe without assigning treatment) · Lead sponsor: Novartis Pharmaceuticals
View the official record on ClinicalTrials.gov →What this trial is about
This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \[SJIA\] and adult-onset Still's disease \[AOSD\]) that received canakinumab for at least 6 months.
Who can take part
Age range
1 Year and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Pediatric or adult patients who were prescribed canakinumab before October 2021 and received canakinumab for at least 6 months for the treatment of FMF or Still's disease (including SJIA or AOSD).
- Have data on clinical characteristics and treatments available for at least 3 years following the initiation of canakinumab treatment.
Exclusion criteria
- Patients Aged \<2 Years (24 Months) at Index Date.
Where it is running
1 location listed.
- Novartis - Basel, Switzerland